Tolvaptan for treating autosomal dominant polycystic kidney disease
In October 2015, NICE recommended that Tolvaptan (JINARC®) therapy should be made available for selected patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in England and Wales In January 2016, the Scottish Medicines Consortium (SMC) also approved Tolvaptan for use in Scotland. Currently Tolvaptan is being used in Canada, Japan, Korea and Switzerland for ADPKD and has been approved for use in Europe by the European Medicines Agency (EMA).
NICE recommended that patients with ADPKD who may be eligible for treatment must have Stage 2 or 3 chronic kidney disease (CKD) and ‘evidence of rapidly progressing disease’. SMC have approved its use for Stages 1-3 CKD, similar to that recommended by the EMA. The definition and evaluation of ‘rapid progression’ are however not established and have not been stipulated by NICE, SMC or the EMA. The main purpose of this commentary is to address the issue of how to identify patients with evidence of or who are at risk of rapid disease progression.
The draft guideline will is available to you for consultation and feedback over the next 3 months; please send your comments to Professor Ong at firstname.lastname@example.org
Please click here to view the draft guideline
Guidelines to Review- Guideline on water treatment systems, dialysis water and dialysis fluid quality for haemodialysis and related therapies
The primary aim of this guideline is to assist the entire multidisciplinary team involved in the provision of water for haemodialysis by providing a single, user friendly document in ensuring the delivery of fit for purpose dialysis water and dialysis fluid.
The second aim of this guideline is to reduce adverse events in the planning, installation, operation and maintenance of water treatment facilities in the UK that may cause risks to patients.
The document which has been peer reviewed and approved by the Association of Renal Technologists and Renal Association. It is NOT intended to replace the National standards and the interpretive guidance MUST be read in conjunction with such National Standards.
The draft guideline will be posted for 4 weeks. Please send all feedback to email@example.com
Click here to view the draft guideline.